Literature DB >> 17047359

Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation.

T Timm1, D Matenia, X-Y Li, B Griesshaber, E-M Mandelkow.   

Abstract

The hyperphosphorylation of tau is an early step in the degeneration of neurons in Alzheimer's disease and other tauopathies. Of particular importance is the phosphorylation of tau in the repeat domain which detaches tau from microtubules. This makes microtubules dynamic for their role in differentiation and neurite outgrowth, and it controls the level of tau on the microtubule surface which keeps the tracks clear for axonal transport. However, the detachment of tau from microtubules can also initiate the reactions that lead to pathological aggregation into neurofibrillary tangles. Phosphorylation of tau in the repeat domain is achieved by the kinase MARK/Par-1, a member of the calcium/calmodulin-dependent protein kinase group of kinases. In this report, we focus on the modes of MARK regulation. MARK contains several domains which offer multiple ways of regulation by posttranslational modification (e.g. phosphorylation), interactions with scaffolding proteins and subcellular targeting (e.g. 14-3-3), and interactions with other proteins. We consider in particular the interactions between MARK and other kinases, notably MARKK/TAO-1 and PAK5. MARKK (a member of the Ste20 family of kinases) activates MARK by phosphorylating it at a critical threonine residue within the activation loop. Activated MARK in turn phosphorylates tau, causes its detachment from microtubules and renders them labile. PAK5 inactivates MARK, not by phosphorylation, but by binding to the catalytic domain. PAK5 contributes to microtubule stability by preventing the MARK-induced phosphorylation of tau; conversely, PAK5 contributes to actin dynamics, presumably through the activation of cofilin, an F-actin severing protein. Thus, MARK and its regulators MARKK and PAK5 appear to mediate the crosstalk between the actin and microtubule cytoskeleton in an antagonistic fashion. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047359     DOI: 10.1159/000095258

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  22 in total

1.  De Novo Variants in TAOK1 Cause Neurodevelopmental Disorders.

Authors:  Marija Dulovic-Mahlow; Joanne Trinh; Krishna Kumar Kandaswamy; Geir Julius Braathen; Nataliya Di Donato; Elisa Rahikkala; Skadi Beblo; Martin Werber; Victor Krajka; Øyvind L Busk; Hauke Baumann; Nouriya Abbas Al-Sannaa; Frauke Hinrichs; Rabea Affan; Nir Navot; Mohammed A Al Balwi; Gabriela Oprea; Øystein L Holla; Maximilian E R Weiss; Rami A Jamra; Anne-Karin Kahlert; Shivendra Kishore; Kristian Tveten; Melissa Vos; Arndt Rolfs; Katja Lohmann
Journal:  Am J Hum Genet       Date:  2019-06-20       Impact factor: 11.025

2.  Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Ismael Santa-Maria; Raúl Mena; Lester I Binder; Jesús Avila; Mark A Smith; George Perry; Francisco García-Sierra
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

3.  Quantitative phosphokinome analysis of the Met pathway activated by the invasin internalin B from Listeria monocytogenes.

Authors:  Tobias Reinl; Manfred Nimtz; Claudia Hundertmark; Thorsten Johl; György Kéri; Jürgen Wehland; Henrik Daub; Lothar Jänsch
Journal:  Mol Cell Proteomics       Date:  2009-07-29       Impact factor: 5.911

4.  Prostate-derived sterile 20-like kinases (PSKs/TAOKs) are activated in mitosis and contribute to mitotic cell rounding and spindle positioning.

Authors:  Rachael L Wojtala; Ignatius A Tavares; Penny E Morton; Ferran Valderrama; N Shaun B Thomas; Jonathan D H Morris
Journal:  J Biol Chem       Date:  2011-06-24       Impact factor: 5.157

5.  Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.

Authors:  Siddhartha Mondragón-Rodríguez; Emilie Trillaud-Doppia; Anthony Dudilot; Catherine Bourgeois; Michel Lauzon; Nicole Leclerc; Jannic Boehm
Journal:  J Biol Chem       Date:  2012-07-25       Impact factor: 5.157

6.  High expression of P21-activated kinase 5 protein is associated with poor survival in gastric cancer.

Authors:  Tomoki Aburatani; Mikito Inokuchi; Yoko Takagi; Toshiaki Ishikawa; Keisuke Okuno; Kentaro Gokita; Chiharu Tomii; Toshiro Tanioka; Hideaki Murase; Sho Otsuki; Hiroyuki Uetake; Kazuyuki Kojima; Tatsuyuki Kawano
Journal:  Oncol Lett       Date:  2017-05-03       Impact factor: 2.967

7.  Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.

Authors:  Kaisheng Mao; Fakeng Liu; Xiuju Liu; Fadlo R Khuri; Adam I Marcus; Mingsong Li; Wei Zhou
Journal:  Lung Cancer       Date:  2015-03-01       Impact factor: 5.705

Review 8.  MAP/microtubule affinity-regulating kinases, microtubule dynamics, and spermatogenesis.

Authors:  Elizabeth I Tang; Dolores D Mruk; C Yan Cheng
Journal:  J Endocrinol       Date:  2013-04-15       Impact factor: 4.286

9.  The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer.

Authors:  Diyou Li; Xiaohong Yao; Ping Zhang
Journal:  Mol Cell Biochem       Date:  2013-07-23       Impact factor: 3.396

Review 10.  PAK signaling in oncogenesis.

Authors:  P R Molli; D Q Li; B W Murray; S K Rayala; R Kumar
Journal:  Oncogene       Date:  2009-05-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.